Brief: Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Brief: Polyrizon Enters Agreement With Global Branding Consultancy Firm
Brief: Polyrizon Ltd. Announces Closing Of $17.0 Million Private Placement
Brief: Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting
Brief: Polyrizon Expands Drug Delivery Innovation With Preclinical Studies For Epilepsy Rescue Treatment
Brief: Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses
Brief: Polyrizon Commences Gmp Manufacturing Preliminary Process
Brief: Polyrizon Ltd Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing
Brief: Polyrizon Announces Closing Of $4.2 Mln IPO